Session 8: Ebola Vaccines and Vaccination

SAGE WORKING GROUP ON EBOLA VACCINES & VACCINATION

SAGE will receive the report of the SAGE Working Group on Ebola vaccines for information and discussion



Members of SAGE Ebola Working Group

Rees, Helen - S. Africa & Tomori, Oyewale - Nigeria (Co-Chairs)

Andrews, Nick - UK	Moodley, Keymanthri - S. Africa
Bonsu, George - Ghana	Ndack, Diop - Senegal
Durrheim, David - Australia	O'Brien, Kate - Canada
Goodman, Jesse - USA	Ockenhouse, Chris - USA
Jemmy, Jean-Paul - Belgium	Velasco Muñoz, Cesar - Spain
Kelly, Ann - UK	Were, Fred - Kenya

Wiysonge, Charles - Cameroon



SAGE Ebola Working Group Ex-Officio Members

Breiman, Robert - Chair IVIR-AC

Griffiths, Ellwyn - Chair ECBS

Morgan, Chris - Chair IPAC

Wharton, Melinda - Chair GACVS

WHO Secretariat

Cherian, Thomas - Focal point



- Facilitate SAGE review of available evidence and advice WHO on the potential post-licensure use of the Ebola vaccines.
- Consult with the Task Force for Immunization for the African region on operationalization of immunization delivery.
- Provide report to SAGE with recommendations on potential strategies for the deployment of Ebola vaccine(s).



Review

- Evidence needed for making policy recommendations and strategies for deployment of vaccines.
- Available epidemiological data to define the risk of disease and mortality in different population groups to allow prioritization of vaccination.
- Evidence on the safety and efficacy of candidate vaccines, including the optimal vaccination schedules to be used for each vaccine.



Review

- •Data on the projected impact of different vaccination strategies generated by mathematical models.
- •Projections of vaccine supply to inform recommendations on the deployment of vaccines.



- Synthesise all above data, and draft recommendations for consideration by SAGE with the objective of:
 - ✓ mitigating the public health impact of the disease and possibly curtailing the ongoing epidemic
 - ✓ preventing or reducing the risk of spread of disease in the future



Activities of the Working Group

- WG conducted three teleconferences between November 2014 and February 2015.
- Held a face-to-face meeting on 9-10 March 2015.
- The WG reviewed the latest available epidemiological data on the status of the current outbreak, the status of vaccine development and the preparations for supporting countries with the deployment of vaccines.
- The WG developed a draft framework for formulating recommendations for vaccine use.



Presentations to SAGE

Introduction, O. Tomori, Ebola WG Co-Chair

Update on the epidemiology of EVD - C. Dye, WHO

Status of phase 1 and 2 trials and summary of preliminary results from phase 1 trials – V. Moorthy, WHO

Update on phase 3 trials (design and status) – AM. Henao-Restrepo, WHO

Preparations for vaccine deployment – MP. Preziosi, WHO

Framework for recommendations for deployment of vaccines – H. Rees, Ebola WG Co-Chair



Discussion and feedback from SAGE

The draft framework will be presented to SAGE for discussion and feedback

